All In Biotech

Free tool

FAERS Monitor: Filspari

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216403 or its brand name (Filspari, Sparsentan). Reports on generic versions are filed under their own applications.

Reports

6,767

Serious

1,116

16% of reports

Hospitalization

477

Death reported

37

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dizziness984
  • fatigue887
  • hypotension750
  • off label use456
  • nausea455
  • headache403
  • product use in unapproved indication390
  • product administration error369
  • peripheral swelling354
  • pruritus317
  • product dose omission issue278
  • blood pressure decreased268
  • glomerular filtration rate decreased253
  • drug ineffective231
  • blood creatinine increased221

Reports by year received

View as table
YearReports
20203
20216
20222
2023632
20241,221
20252,395
20262,508

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,392 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
glomerular filtration rate decreasedSignal25365.357.815,642
product administration errorSignal36957.852.320,179
blood pressure decreasedSignal26812.611.22,843
hypotensionSignal75011.710.97,342
blood creatinine increasedSignal22110.69.31,901
peripheral swellingSignal3547.26.51,878
dizzinessSignal9846.15.84,325
product use in unapproved indicationSignal3904.94.41,218
fatigueSignal8873.53.31,678
product dose omission issueSignal2782.92.6359
pruritusSignal3172.62.3307
headache4032.01.8206
nausea4551.81.6163
off label use4561.61.5112
drug ineffective2310.50.593

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.